MS Flashcards

1
Q

definition of MS

A

–chronic, inflammatory autoimmune
–potentially disabling disease (brain and spinal cord)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

characteristics of MS

A

–inflammation
–demyelination
–scar development

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

etiology of MS

A

–unknown
–autoimmune may be triggered by infection
–genetic predisposition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

risk factors for MS

A

–age: 20-40
–gender: women
–location: moderately cool climate (Northern US)
–race: Caucasian
—-genetics: family hx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

possible risk factors for MS

A

–smoking
–vitamin D deficiency
–obesity
–infection (Epstein Barr)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

patho of MS

A

–consists of autoimmune attack against the myelin sheath
–T lymphocytes migrate to CNS and cross the blood brain barrier
–antigen-antibody reaction in CNS initiates an inflammatory response
–axons are demyelinated and plaques/sclerosis forms
–axons are destroyed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

early disease effects of MS on nerves

A

–nerve fiber not affected
–impulses still transmitted
–may notice weakness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

later disease effects of MS on nerves

A

–axons are destroyed
–impulses are totally blocked
–permanent loss of function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

types of disease progression with MS

A

–benign
–relapsing-remitting
–primary-progressive
–secondary-progressive
–progressive-relapsing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

benign progression of MS

A

no disability with a return to normal between attacks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

relapsing-remitting progression of MS

A

unpredictable attacks which may leave permanent deficits followed by periods of remission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

primary-progressive progression of MS

A

steady increase in disability without attacks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

secondary-progressive progression of MS

A

initial relapsing-remitting MS that suddenly begins to decline without periods of remission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

progressive-relapsing progression of MS

A

steady decline since disease onset with superimposed attacks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

symptoms of MS

A

–numbness, tingling
–walking difficulty
–pain
–fatigue
–muscle spasms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

symptoms to monitor with MS

A

–cognitive problems (Cog Fog)
–vision problems
–depression
–fatigue
–pain
–bowel/bladder
–weakness
–sexual issues
–muscle stiffness/spasm
–walking/balance (vertigo; fall risk)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

goals of therapy for MS

A

–slow disability
–reduce frequency of relapses
–reduce new brain lesions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what are drugs used for with MS?

A

–modify disease process
–treat acute relapse
–manage symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

which MS drug is an injectable - interferon beta?

20
Q

which MS drug is an injectable - glatiramer acetate?

21
Q

MOA of avonex

A

inhibit pro-inflammatory WBCs from crossing BBB

22
Q

adverse effects of avonex

A

–flu-like reactions
–liver toxicity
–bone marrow suppression
–depression
–drug interactions

23
Q

effectiveness of avonex

A

decreases relapse rate by up to 30%

24
Q

MOA of copaxone

A

increased production of anti-inflammatory T cells which cross the BBB and suppress inflammation

25
adverse effects of copaxone
--injection site reactions --post-injection reactions (flushing, palpitations, chest pain, rash, laryngeal constriction)
26
how long do side effects of copaxone last?
15-20 minutes
27
oral MS meds
--fingolimod --dimethyl fumarate
28
infusion MS meds
natalizumab
29
MOA of fingolimod
retain lymphocytes in the lymph nodes, preventing them from crossing the BBB -- decreasing inflammation
30
which progression stage does fingolimod target?
RRMS
31
MOA for dimethyl fumarate
thought to inhibit immune cells and may have antioxidant properties
32
MOA of natalizumab
prevents circulating T cells from leaving the vasculature and crossing the BBB
33
therapeutic uses of natalizumab
MS and Crohn's
34
specifics about natalizumab
--monotherapy only --relapsing form of MS
35
adverse effects of natalizumab
--most common = HA, fatigue --progressive multifocal leukoencephalopathy (PML) --hepatotoxicity --hypersensitivity
36
progressive multifocal leukoencephalopathy
--drug only available through TOUCH prescribing program --risk increases when combined with another immunosuppressant
37
TOUCH prescribing program
only prescribers, infusion sites, and their associated pharmacies enrolled with the program are able to prescribe, distribute, or infuse
38
alemtuzumab
--infusion --reserved for patients with poor response to 2 or more MS meds
39
mitoxantrone
--secondary progressive --progressive-relapsing --worsening RRMS
40
preferred treatment for acute relapses
--high dose IV glucocorticoid (frequent use or long-term use should be avoided) --IV gamma globulin (for patients intolerant to glucocorticoids)
41
ACTH in treating acute relapse
--ACTH in gel form --prolonged release of ACTH after injection --unable to tolerate steroids or they have not been effective
42
MS drug used to treat urinary frequency/retention
--anticholinergics --cholinergics
43
MS drugs used to treat constipation
bulk-forming laxative
44
MS drugs used to treat fatigue
amantadine
45
MS drugs used to treat muscle spasms
muscle relaxants
46
MS drugs used to treat cognitive dysfunction
donepezil